Roivant Sciences Ltd insider trades
as of filings through Nov 5, 2026
- Bought
- $0
- 0 trades, 0 insiders
- Sold
- $30.8M
- 8 trades, 3 insiders
- Net
- −$30.8M
- since Sep 10, 2026
- Under 10b5-1 plans
- 8
- of 8 sales
FiledStockInsiderSideValueSharesAvg priceTraded
- Filed Nov 5, 6:11 PM (the Form 4 at the SEC), traded Nov 3ROIVSoldEric Venker · President & Immunovant CEOPlan$7.3M
- Filed Oct 30, 6:29 PM (the Form 4 at the SEC), traded Oct 28ROIVSoldEric Venker · President & Immunovant CEOPlan$7.3M
- Filed Oct 22, 6:44 PM (the Form 4 at the SEC), traded Oct 20ROIVSoldEric Venker · President & Immunovant CEOPlan$7.0M
- Filed Oct 5, 6:05 PM (the Form 4 at the SEC), traded Oct 1 · 4d late to fileROIVSoldMelissa B, Epperly · DirectorPlan$641K
- Filed Oct 2, 5:37 PM (the Form 4 at the SEC), traded Sep 30ROIVSoldEric Venker · President & Immunovant CEOPlan$7.3M
- Filed Sep 17, 6:43 PM (the Form 4 at the SEC), traded Sep 15ROIVSoldMelissa B, Epperly · DirectorPlan$196K
- Filed Sep 17, 6:42 PM (the Form 4 at the SEC), traded Sep 15ROIVSoldMeghan Fitzgerald · DirectorPlan$203K
- Filed Sep 10, 9:00 PM (the Form 4 at the SEC), traded Sep 8ROIVSoldMeghan Fitzgerald · DirectorPlan$798K
More on ROIV
ROIV against its rivals
No comparison pages for ROIV.